Rachel Hendricks

Certified genetic counselor

[NSGC Student/New Member SIG @NSGC_SNG_SIG]

#GeneChat 📝Applications for the Student/New Grad SIG Executive Team are OPEN! Support current and prospective #geneticcounseling students and GCs through projects and initiatives that strengthen our community. Apps due by January 2nd, 2026

Apply here: https://t.co/SENofZ0Gaj

[NSGC Student/New Member SIG @NSGC_SNG_SIG]

📣 Genetic counseling students and new grads: the Student/New Grad Special Interest Group (SIG) through NSGC is a great way to connect with peers, access valuable resources, and stay informed about study groups, funding opportunities, and professional initiatives! #GeneChat 1/2

[ESH (Haematology) @ESHaematology]

#ESHCONFERENCES We got a great wrap up from Lisa McReynolds on genome-first-approach in leukemia diagnosis and characterisation leading to interesting discussions at #ESHBMFS2024 #BMFsm #ESHELEARNING

[HemeHub @HemeHub]

#BMFCases at #ASH24

Lisa J. McReynolds, MD, PhD, examines germline variants in key myeloid genes like #DDX41 and #GATA2, highlighting their impact on #BloodCancer risk.

Sunday, Dec 8, 2024 | 10:45 AM

@ASH_hematology #hemeTwitter #MedX

[Harry Layton Lesmana, MD @harry_lesmana]

Lisa McReynolds of @NIH investigated prevalence and penetrance of #germline mutations in 8 genes predisposing to myeloid malignancy using genome first approach:
- Higher prevalence than expected 1 in 448-603, DDX41 is most common
- High penetrance for RUNX1, ETV6, GATA2 #ASH24

[Dr. David J. Young, MD PhD @DrDavidJYoung]

Love is all around…and so are variants.

Dr. Lisa McReynolds: @NCICancerBio IBMFS/CPS genes may be as prevalent as about 0.2%, with high penetrance. Some of these are associated with higher and/or earlier rates of malignant transformation. We need management guidelines #ASH24

[Rachel Hendricks @rachmhendricks]

Excited to share my work determining the prevalence and penetrance of eight germline myeloid malignancy predisposition genes has been selected for oral presentation at #ASH24!

After you #vote, check out all the amazing cutting edge topics that will be discussed in December!

[ASH @ASH_hematology]

The #ASH24 abstracts are live! See the amazing scientific breakthroughs being presented at the ASH annual meeting.

View them now: https://t.co/Lbpv4e5LKI

Experience the science in San Diego or virtually. Registration is still open!

[NSGC Student/New Member SIG @NSGC_SNG_SIG]

#GeneChat We are now on LinkedIn! Follow the NSGC Student/New Member SIG here: https://t.co/y9MJl3sc4u

[NSGC Student/New Member SIG @NSGC_SNG_SIG]

It’s boards study season! 🧬 If you are interested in participating in an August 2024 ABGC study groups organized through the Student and New Grad SIG, please complete this form by Friday, May 24th, 2024.

https://t.co/DmM1mLAW8R

[Emma M. Groarke @emmamgroarke]

Lisa McReynolds from @theNCI discusses the role of genetic testing in #SAA and #MDSsm. @aamdsif

[Team Telomere @TeamTelomereInc]

We are excited to announce the launch of our new educational resource collection: one-pagers! Developed based on our Telomere Biology Disorders Guidelines, these concise resources make complex TBD info easily accessible. Access them on our website!
*link https://t.co/Kn40V0A58T

[Genetics in Medicine @GIMJournal]

Do #Fanconi Anemia heterozygotes have an increased #cancer risk? It looks like the long awaited answer is likely to be no. #genomefirst #DiscovEHR #populationgenetics https://t.co/06nqQH4Umq

[Emma M. Groarke @emmamgroarke]

Lisa McReynolds from @NCIEpiTraining shows at the germline predisposition workshop that FA relatives do not have an increased risk of cancer. #ASH23 @ASH_hematology @SharonSavageMD

[ASH @ASH_hematology]

Today we honor Dr. Blanche P. Alter, MD, MPH, of @theNCI, with the 2023 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Her groundbreaking work in inherited #bmfsm syndromes has revolutionized cancer research and patient care. https://t.co/Q6RMJfpz1d #ASH23

[Burak Altintas @AltintasBurakMD]

Don’t miss Lisa McReynolds, MD PhD at #ASH23 workshop on Germline Predisposition to Hematopoietic Malignancies and BMF on Dec 8, sharing the results of our genome-first population study investigating the cancer risk in people w/ heterozygous FA variants. Paper coming out soon!🧬

[Emma M. Groarke @emmamgroarke]

Just a week to go until #ASH23! Wanted to let everyone know will be having an education session on #IBMFS with myself, Marena Niewisch, @Olson__Lab where will discuss general #BMFsm diagnostics + particulars of #FA and #TBD. Hope to see you all there ☀️2pm 12/9. @ASH_hematology

[ClinGen @ClinGenResource]

On #GeneticCounselorAwarenessDay ClinGen celebrates the 275 genetic counselors who contribute to our work. To learn more about genetic counseling, watch ClinGen's genetic counseling career panel from our 2023 Clinical Genomics Careers Panel Series https://t.co/Nwxy3x1gw3

[Human Genetics and Genomics Advances @HGGAdvances]

📢New @HGGAdvances
📰Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants
🧑‍🤝‍🧑@SharonSavageMD & colleagues
👉https://t.co/wen6Pg858s

[Sharon A. Savage, M.D. @SharonSavageMD]

Cancer risk in heterozygotes of 15 #FanconiAnemia genes not increased (except in known CPGs BRCA1/2, PALB2, BRIP1, RAD51C). Many FA relatives can breath a sigh of relief. Led by Dr Lisa McReynolds #NCI_ClinicalGenetics @NCIEpiTraining @FAresearchfund symposium #FARF23

[ClinGen @ClinGenResource]

ClinGen’s 5th genomics career panel will be July 26th at 12pm ET. Hear about roles including genetic counseling assistant & biocurator and how they can help individuals gain experience & knowledge before further schooling and jobs. Register here https://t.co/1DxRmyoMR1 #genetics